Enhanced oral bioavailability of tacrolimus in rats by self- microemulsifying drug delivery systems

Drug Development and Industrial Pharmacy

Volumn 37, Issue 10, 2011, Pages 1225-1230

  Wang, Yongjun ^a   Sun, Jin ^a   Zhang, Tianhong ^a   Liu, Hongzhuo ^a   He, Fancui ^a   He, Zhonggui ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Cremophor; P glycoprotein; SMEDDS; Tacrolimus; TPGS

Indexed keywords

CASTOR OIL; COSURFACTANT; CREMOPHOR; DIETHYLENE GLYCOL MONOETHYL ETHER; EXCIPIENT; GLYCOPROTEIN P; MACROGOL 200; MIGLYOL; PROPYLENE GLYCOL; TACROLIMUS; TOCOFERSOLAN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOCOMPATIBILITY TEST; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MICROEMULSION; NONHUMAN; PARTICLE SIZE; RAT; SELF MICROEMULSIFYING DRUG DELIVERY SYSTEM; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ABSORPTION; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; EMULSIFYING AGENTS; EMULSIONS; IMMUNOSUPPRESSIVE AGENTS; MALE; P-GLYCOPROTEIN; PARTICLE SIZE; POLYETHYLENE GLYCOLS; RATS; RATS, WISTAR; SOLUBILITY; TACROLIMUS;

EID: 80052511398     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2011.565774     Document Type: Article

References (30)

1. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramman R, Jain A. (1989). FK 506 for liver, kidney, and pancreas transplantation. Lancet, 2:1000-1004 (Pubitemid 19257914)
2. Hooks MA. (1994). Tacrolimus, a new immunosuppressant-a review of the literature. Ann Pharmacother, 28:501-511 (Pubitemid 24123768)
3. Waldrep JC. (1998). New aerosol drug delivery systems for the treatment of immune-mediated pulmonary diseases. Drugs Today, 34:549-561 (Pubitemid 28331558)
4. Venkataramanan R, Shaw LM, Sarkozi L, Mullins R, Pirsch J, MacFarlane G et al. (2001). Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J Clin Pharmacol, 41:542-551 (Pubitemid 32381872)
5. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V et al. (1995). Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet, 29:404-430 (Pubitemid 26004179)
6. Uno T, Yamaguchi T, Li XK, Suzuki Y, Hashimoto H, Harada Y et al. (1997). The pharmacokinetics of water-in-oil-in-watertype multiple emulsion of a new tacrolimus formulation. Lipids, 32:543-548 (Pubitemid 27213325)
7. McAlister VC, Keshavamurthy M, Lee TD. (1999). Oral delivery of liposomal tacrolimus: increased efficacy and reduced toxicity. Transplant Proc, 31:1110 (Pubitemid 29127830)
8. Arima H, Yunomae K, Miyake K, Irie T, Hirayama F, Uekama K. (2001). Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats. J Pharm Sci, 90:690-701 (Pubitemid 32530445)
9. Yamashita K, Nakate T, Okimoto K, Ohike A, Tokunaga Y, Ibuki R et al. (2003). Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int J Pharm, 267:79-91 (Pubitemid 37352952)
10. Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y. (2005). A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles. J Control Release, 104:337-346 (Pubitemid 40724934)
11. Nassar T, Rom A, Nyska A, Benita S. (2009). Novel double coated nanocapsules for intestinal delivery and enhanced oral bioavailability of tacrolimus, a P-gp substrate drug. J Control Release, 133:77-84
12. Shin SB, Cho HY, Kim DD, Choi HG, Lee YB. (2010). Preparation and evaluation of tacrolimus-loaded nanoparticles for lymphatic delivery. Eur J Pharm Biopharm, 74:164-171
13. ODriscoll CM. (2002). Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci, 15:405-415
14. Porter CJ, Kaukonen AM, Taillardat-Bertschinger A, Boyd BJ, OConnor JM, Edwards GA et al. (2004). Use of in vitro lipid digestion data to explain the in vivo performance of triglyceridebased oral lipid formulations of poorly water-soluble drugs: studies with halofantrine. J Pharm Sci, 93:1110-1121 (Pubitemid 38529685)
15. Patel D, Sawant KK. (2007). Oral bioavailability enhancement of acyclovir by self-microemulsifying drug delivery systems (SMEDDS). Drug Dev Ind Pharm, 33:1318-1326
16. Dintaman JM, Silverman JA. (1999). Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res, 16:1550-1556 (Pubitemid 29510551)
17. Collnot EM, Baldes C, Wempe MF, Kappl R, Hüttermann J, Hyatt JA et al. (2007). Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity. Mol Pharm, 4:465-474 (Pubitemid 46983960)
18. Shono Y, Nishihara H, Matsuda Y, Furukawa S, Okada N, Fujita T et al. (2004). Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes. J Pharm Sci, 93:877-885 (Pubitemid 38420399)
19. Kommuru TR, Gurley B, Khan MA, Reddy IK. (2001). Selfemulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment. Int J Pharm, 212:233-246 (Pubitemid 32119449)
20. Hauss DJ, Fogal SE, Ficorilli JV, Price CA, Roy T, Jayaraj AA et al. (1998). Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor. J Pharm Sci, 87:164-169 (Pubitemid 28081323)
21. Charman WN, Stella VJ. (1991). Transport of lipophilic molecules by the intestinal lymphatic system. Adv Drug Deliv Rev, 7:1-14
22. Scott Swenson E, Curatolo WJ. (1992). (C) Means to enhance penetration: (2) Intestinal permeability enhancement for proteins, peptides and other polar drugs: mechanisms and potential toxicity. Adv Drug Deliv Rev, 8:39-92
23. Yang S, Gursoy RN, Lambert G, Benita S. (2004). Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm Res, 21:261-270 (Pubitemid 38221971)
24. Varma MV, Panchagnula R. (2005). Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci, 25:445-453 (Pubitemid 40853872)
25. Yin YM, Cui FD, Mu CF, Choi MK, Kim JS, Chung SJ et al. (2009). Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation. j Control Release, 140:86-94
26. Rege BD, Kao JP, Polli JE. (2002). Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci, 16:237-246
27. Solomon MB, Meenan B, Heavey C, Paietta E. (1995). Differential modulation of P-glycoprotein, the multidrug resistance mediator, by Cremophor in normal versus leukemic hematopoietic cells. Blood, 86:4385-4386
28. Collnot EM, Baldes C, Schaefer UF, Edgar KJ, Wempe MF, Lehr CM. (2010). Vitamin E TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access. Mol Pharm, 7:642-651
29. Kaplan B, Lown K, Craig R, Abecassis M, Kaufman D, Leventhal J et al. (1999). Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. Transplantation, 67:333-335 (Pubitemid 29066365)
30. Yokogawa K, Takahashi M, Tamai I, Konishi H, Nomura M, Moritani S et al. (1999). P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdr1a knockout mice. Pharm Res, 16:1213-1218 (Pubitemid 29393609)